Novel Crystalline Forms of Entacapone and Production Thereof
OwnerThomas Bader, Markus Furegati +1inventors
InventorsThomas Bader, Markus Furegati, Oliver Jungmann
Life of this patent
Estimating the term…
Loading patent…
OwnerThomas Bader, Markus Furegati +1inventors
InventorsThomas Bader, Markus Furegati, Oliver Jungmann
Estimating the term…
The invention relates to three novel forms of entacapone. These are peripheral and selective COMT inhibitors which in combination with levodopa and decarboxylase inhibitors can be used to treating Parkinson's syndrome. Said novel forms arise by crystallization of entacapone in respectively determined conditions. In certain cases, entacapone can be used as a raw product, in a special case it can be used in situ as the product of Knoevenagel condensation of 3,4-dihydroxy-5-nitro-benzaldehyde and N,N-diethyl-2-cyanoacetamide. Also disclosed are improvements of said condensation in relation to the catalyst and the production of the two components thereof.
A crystalline form C of entacapone, characterized by the following XRD data:
A crystalline form D of entacapone, characterized by the following XRD data:
A crystalline form E of entacapone, characterized by the following XRD data:
A process for the preparation of entacapone by a Knoevenagel condensation of 3,4-dihydroxy-5-nitrobenzaldehyde and N,N-diethyl-2-cyanoacetamide, characterized in that the catalyst used for this condensation is diethylamine/acetic acid.
Dependencies are inferred from the claim text.